Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

176

Participants

Timeline

Start Date

July 25, 2005

Primary Completion Date

March 28, 2008

Study Completion Date

March 28, 2008

Conditions
Myelodysplastic SyndromeIron Overload
Interventions
DRUG

Deferasirox

20 mg/kg/day over one year in patients with MDS

Trial Locations (48)

14621

Rochester General Hospital/Lipson Cancer and Blood Center, Rochester

14623

Roswell Park Cancer Center, Buffalo

15224

Western Pennsylvania Hospital Cancer Institute, Pittsburgh

19107

Thomas Jefferson University; Jefferson Medical College, Kimmel Cancer Center, Philadelphia

22205

Arlington Fairfax Hematology Oncology PC, Arlington

28801

Cancer Care of WNC, Asheville

30322

Emory University School of Medicine/Winship Cancer Institute, Atlanta

32224

Mayo Clinic, Jacksonville

35294

Univ of Alabama Birmingham, Birmingham

37232

Novartis Investigative site, Nashville

38120

The West Cancer Clinic, Memphis

43210

The Ohio State University, Columbus

44195

The Cleveland Clinic Foundation, Cleveland

48075

Novartis Investigative Site, Southfield

53226

Medical College of Wisconsin, Milwaukee

55905

Mayo Clinic, Rochester

60612

Novartis Investigative Site, Chicago

63110

The Center for Cancer Care & Research (TCCCR), St Louis

66160

University of Kansas Medical Center, Kansas City

71301

Cabrini Center for Cancer Care/Christus St. Frances Cabrini Hospital, Alexandria

77030

Baylor/The Methodist Hospital, Houston

80012

Rocky Mountain Cancer Centers, Aurora

84106

Utah Cancer Specialists, Salt Lake City

85054

Mayo Clinic, Phoenix

87109

NMOHC, Albuquerque

90048

Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles

91010

City of Hope National Medical Center, Duarte

94143

UCSF, San Francisco

94520

Bay Area Cancer Research Group, Concord

96813

Straub Clinic and Hospital, Honolulu

97239

Novartis Investigative Site, Portland

99202

Novartis Investigative Site, Spokane

90095-1678

UCLA Medical Center, Los Angeles

94143-0324

UCSF, San Francisco

60637-1470

University of Chicago Hospital, Chicago

40536-0093

University of Kentucky College of Medicine, Markey Cancer Center, Lexington

21231-1000

St. Agnes HealthCare, Baltimore

01605

Rush Cancer Institute Univ. of Massachussets Medical Center, Worcester

68124-2346

Oncology Hematology West, PC, Omaha

03756-0001

Dartmouth Hitchcock Medical Center, Lebanon

07601

The Cancer Center at Hackensack University, Hackensack

27157-1082

Wake Forest UniversitComprehensive Cancer Center, Winston-Salem

V6Z 1Y6

Novartis Investigative Site, Vancouver

L8N 3Z5

Novartis Investigative Site, Hamilton

M4N 3M5

Novartis Investigative Site, Toronto

M5g 2M9

Novartis Investigative Site, Toronto

H1T 2M4

Novartis Investigative Site, Montreal

H2L 4M1

Novartis Investigative Site, Montreal

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY